ClinicalTrials.gg
RecruitingNCT06859775Updated Jun 6, 2025

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

A Phase 1/2 interventional study of SHR-A1811 and Adebelimab injection in Recurrent or Metastatic Cervical Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-06.

Primary conditionUterine Cervical NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Uterine Cervical Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Uterine Cervical Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
163rd of 360
100 · median 90
Started
2025
with 43 others
Phase 1/2
26 of 455
13 open now
Primary completion
2026-10
later than 124 of 239 live
Registered
392nd of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 163rd largest by planned enrollment of the 360 interventional ones that give a count, is one of 44 that started in 2025, is one of 26 in phase 1/2, reaches primary completion later than 124 of the 239 other live ones, and was the 392nd registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.

03

Conditions studied

  • Recurrent or Metastatic Cervical Cancer

Browse trials for

04

In context

Uterine Cervical Neoplasms Reclassified

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Compared within Uterine Cervical Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily join this study, sign the form, have good compliance and be able to cooperate with the follow-up.
  2. Female, aged 18-75 years old.
  3. Expected survival ≥ 12 weeks.
  4. Normal function of vital organs.
  5. Female subjects of must have a negative serum HCG test within 7 days prior to the first dose and must be non-lactating.
  6. Female subjects must agree to comply with requirements from signing the informed consent form to 7 months after the last dose of the drug.

Exclusion criteria

Exclusion Criteria:

  1. Previous or concomitant other .
  2. Severe bone damage caused by bone from tumours.
  3. Presence of active disease or history of autoimmune disease with possible recurrence.
  4. Those with active tuberculosis.
  5. Concomitant poorly controlled or severe cardiovascular disease.
  6. Occurrence of arteriovenous thrombotic events within 6 months prior to the first dose.
  7. Presence of gastrointestinal obstruction or presence of symptoms and signs of gastrointestinal obstruction within 6 months prior to the first dose.
  8. Subjects who have had a serious infection within 1 month before the first dose.
  9. Subjects who have a history of immunodeficiency.
  10. As judged by the investigator, there are other factors that may affect the results of the study or cause the study to be forced to terminate halfway.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Treatment cohort 1

    Drug: SHR-A1811 · Drug: Adebelimab injection · Drug: Bevacizumab injection

  • Experimental
    Treatment cohort 2

    Drug: SHR-A1811 · Drug: Adebelimab injection · Drug: Bevacizumab injection · Drug: SHR-8068

  • Experimental
    Treatment cohort 3

    Drug: SHR-A1811 · Drug: Adebelimab injection · Drug: Bevacizumab injection · Drug: SHR-8068 · Drug: Cisplatin injection · Drug: Carboplatin injection

Interventions

07

What researchers measure

Primary outcomes

  1. Grade≥3 drug-related adverse events (TRAEs).

    Time frame: Up to 3 years.

  2. Grade≥3 drug-related serious adverse events (TRAEs).

    Time frame: Up to 3 years.

  3. Objective response rate (ORR).

    Time frame: Up to 3 years.

Secondary outcomes

  1. Duration of response (DOR).

    Time frame: Up to 3 years.

  2. Disease control rate (DCR).

    Time frame: Up to 3 years.

  3. Progression-free survival (PFS).

    Time frame: Up to 3 years.

  4. Overall survival (OS).

    Time frame: Up to 3 years.

08

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100730, China
    Recruiting
    • Yang Xiang · ContactXiangY@pumch.cn · +86-010-69156086
    • Yang Xiang · Principal investigator
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2026, 18 months after the start.

Of 53 industry-sponsored phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 75. This study's planned 18 months is below that.

Counting every sponsor, half of 81 studies reached it within 62 months; a quarter within 36 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 5, 2025
StartActual
Apr 25, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Jan 2027
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06859775
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Apr 25, 2025
Primary completion
Oct 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jun 6, 2025

Study contacts

Na An
Contact
na.an@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion